MX2019015396A - El uso de amisulpride como un anti-emetico. - Google Patents

El uso de amisulpride como un anti-emetico.

Info

Publication number
MX2019015396A
MX2019015396A MX2019015396A MX2019015396A MX2019015396A MX 2019015396 A MX2019015396 A MX 2019015396A MX 2019015396 A MX2019015396 A MX 2019015396A MX 2019015396 A MX2019015396 A MX 2019015396A MX 2019015396 A MX2019015396 A MX 2019015396A
Authority
MX
Mexico
Prior art keywords
amisulpride
emetic
therapy
retches
utilise
Prior art date
Application number
MX2019015396A
Other languages
English (en)
Inventor
Clive Gilbert Julian
William Gristwood Robert
Cooper Nicola
Fox Gabriel
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019015396(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of MX2019015396A publication Critical patent/MX2019015396A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El amisulpride se usa en la terapia de náusea, vómito o bascas. La terapia puede utilizar una formulación inyectable novedosa, en forma de dosificación unitaria, que comprende menor que 50 mg de amisulpride.
MX2019015396A 2010-03-11 2012-09-07 El uso de amisulpride como un anti-emetico. MX2019015396A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use

Publications (1)

Publication Number Publication Date
MX2019015396A true MX2019015396A (es) 2020-02-07

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012010411A MX2012010411A (es) 2010-03-11 2011-03-10 El uso amisulpride como un anti-emetico.
MX2015003664A MX370629B (es) 2010-03-11 2011-03-10 El uso de amisulpride como un anti-emetico.
MX2019015396A MX2019015396A (es) 2010-03-11 2012-09-07 El uso de amisulpride como un anti-emetico.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012010411A MX2012010411A (es) 2010-03-11 2011-03-10 El uso amisulpride como un anti-emetico.
MX2015003664A MX370629B (es) 2010-03-11 2011-03-10 El uso de amisulpride como un anti-emetico.

Country Status (27)

Country Link
US (11) US9084765B2 (es)
EP (3) EP2567690B1 (es)
JP (2) JP5886213B2 (es)
KR (1) KR101738201B1 (es)
CN (1) CN102892407B (es)
AU (1) AU2011225898B2 (es)
BR (1) BR112012022746B1 (es)
CA (1) CA2792392C (es)
CY (3) CY1115485T1 (es)
DK (3) DK2567690T3 (es)
EA (1) EA030335B1 (es)
ES (3) ES2496092T3 (es)
GB (1) GB201004020D0 (es)
HK (1) HK1179152A1 (es)
HR (3) HRP20140745T1 (es)
HU (1) HUE037088T2 (es)
IL (1) IL221746A (es)
LT (1) LT2796171T (es)
MX (3) MX2012010411A (es)
NO (1) NO2796171T3 (es)
NZ (1) NZ602279A (es)
PL (3) PL2567690T3 (es)
PT (3) PT2796171T (es)
RS (3) RS53466B (es)
SI (3) SI2544657T1 (es)
SM (2) SMT201400127B (es)
WO (1) WO2011110854A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
JP2018530744A (ja) 2015-09-02 2018-10-18 カリフォルニア インスティチュート オブ テクノロジー 低濃度の硫化水素ガスの分光学的検出のための方法および装置
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
JP7268026B2 (ja) 2017-12-05 2023-05-02 サノビオン ファーマシューティカルズ インク 非ラセミ混合物およびその使用
CN114401717A (zh) 2019-06-04 2022-04-26 赛诺维信制药公司 修饰释放配制品及其用途
EP3980008A4 (en) * 2019-06-04 2023-06-28 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US20230263770A1 (en) 2020-07-06 2023-08-24 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
CA3066426A1 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8138169B2 (en) * 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
SMT201400127B (it) 2015-05-05
BR112012022746A2 (pt) 2016-07-05
US20130022688A1 (en) 2013-01-24
US9889118B2 (en) 2018-02-13
HRP20180436T1 (hr) 2018-05-04
US20180042896A1 (en) 2018-02-15
EP2544657B1 (en) 2014-07-16
US20220296570A1 (en) 2022-09-22
US20140147517A1 (en) 2014-05-29
US20180353473A1 (en) 2018-12-13
HRP20140744T1 (hr) 2014-09-26
DK2567690T3 (da) 2014-08-11
US20150335616A1 (en) 2015-11-26
EA030335B1 (ru) 2018-07-31
AU2011225898A1 (en) 2012-10-04
KR20130045241A (ko) 2013-05-03
ES2665418T3 (es) 2018-04-25
US10085970B2 (en) 2018-10-02
SI2544657T1 (sl) 2014-12-31
PT2567690E (pt) 2014-09-03
IL221746A (en) 2017-03-30
EP2567690B1 (en) 2014-07-16
JP5886213B2 (ja) 2016-03-16
CY1115485T1 (el) 2017-01-04
JP2013522181A (ja) 2013-06-13
RS53467B (en) 2014-12-31
PL2544657T3 (pl) 2014-10-31
NZ602279A (en) 2014-08-29
MX2012010411A (es) 2012-11-30
US20210228543A1 (en) 2021-07-29
HUE037088T2 (hu) 2018-08-28
US9119836B2 (en) 2015-09-01
US20200093792A1 (en) 2020-03-26
MX370629B (es) 2019-12-18
CY1115487T1 (el) 2017-01-04
SI2567690T1 (sl) 2014-12-31
PL2567690T3 (pl) 2014-11-28
US20170087128A1 (en) 2017-03-30
KR101738201B1 (ko) 2017-05-19
BR112012022746B1 (pt) 2021-09-28
EP2544657A2 (en) 2013-01-16
EP2796171A1 (en) 2014-10-29
US9084765B2 (en) 2015-07-21
SMT201400126B (it) 2015-05-05
RS53466B (en) 2014-12-31
LT2796171T (lt) 2018-05-10
WO2011110854A2 (en) 2011-09-15
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
SI2796171T1 (en) 2018-05-31
CN102892407A (zh) 2013-01-23
GB201004020D0 (en) 2010-04-21
EP2567690A1 (en) 2013-03-13
NO2796171T3 (es) 2018-06-30
CN102892407B (zh) 2016-03-23
AU2011225898B2 (en) 2014-07-03
JP6279526B2 (ja) 2018-02-14
US20230144973A1 (en) 2023-05-11
US9545426B2 (en) 2017-01-17
CA2792392C (en) 2018-06-19
HRP20140745T1 (hr) 2014-09-26
DK2796171T3 (en) 2018-05-07
DK2544657T3 (da) 2014-08-11
JP2016028090A (ja) 2016-02-25
RS57032B1 (sr) 2018-05-31
US20130022689A1 (en) 2013-01-24
ES2496099T3 (es) 2014-09-18
PT2544657E (pt) 2014-09-03
US8686019B2 (en) 2014-04-01
PT2796171T (pt) 2018-04-24
EA201290833A1 (ru) 2013-09-30
CY1120170T1 (el) 2018-12-12
US10525033B2 (en) 2020-01-07
ES2496092T3 (es) 2014-09-18
CA2792392A1 (en) 2011-09-15
EP2796171B1 (en) 2018-01-31
HK1179152A1 (zh) 2013-09-27

Similar Documents

Publication Publication Date Title
MX2019015396A (es) El uso de amisulpride como un anti-emetico.
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
RS53574B1 (en) PYROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
EP3626253A3 (en) Stable formulations of linaclotide
GB201111485D0 (en) Drug composition and its use in therapy
UA109037C2 (uk) Триазолопіридини
MY177027A (en) Novel dosage and formulation
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
WO2014056824A3 (en) Oral care composition
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
WO2013173803A3 (en) Formulations of amoxicillin and clavulanate potassium and methods for using same
CL2008002485A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para el tratamiento de la endometriosis con reduccion de los efectos colaterales terapeuticos; procedimiento de preparacion de una composicion farmaceutica que comprende a dichos compuestos.
WO2015065628A3 (en) Laquinimod combination therapy for treatment of multiple sclerosis
MX2009008873A (es) Composicion util para el tratamiento de diabetes tipo 2.